San Francisco Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in San Francisco
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
San Francisco News
Military spending remains cornerstone of San Diego's economy, impact report reveals
The military continues to play a vital role in powering San Diego's economy, supporting nearly 357,000 local jobs and contributing .3 billion to the region's total economic output, according to the ...
‘Botcha Buster’ system developed by high school students aims to help detect double-dead meat
Students from San Miguel National High School introduced an innovation designed to detect botcha, or double-dead meat, with the help of artificial intelligence.
Code-gen startup Cursor nearly triples its valuation in Coatue-led funding round
Code-generation startup Cursor nearly tripled its valuation to .3 billion in five months after raising .3 billion in its latest funding round.
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may ...